Work

Long-term outcomes of platinum-based chemotherapy for T4 stage sinonasal adenoid cystic carcinoma

Year: 2025

Type: article

Abstract: Purpose: To investigate the impact of platinum-based chemotherapy on long-term outcomes of T4 sinonasal adenoid cystic carcinoma (SNACC). Methods: We retrospectively analyzed clinical data from 87 consecutive patients with T4 SNACC who underwent surgery plus radiotherapy with or without platinum-based chemotherapy in our institution between 1993 and 2019. Results: Of the 87 cases of T4 SNACC, 57.5% (50/87) of patients underwent platinum-based chemotherapy. Overall, chemotherapy was not associated with overall survival (OS) (P = 0.814), PFS (progression-free survival) (P = 0.508), local recurrence-free survival (LRFS) (P = 0.500) or distant metastasis-free survival (DMFS) (P = 0.202) improvement. Besides, chemotherapy significantly decreased 10-year OS (27.9% vs. 58.8%, P = 0.034) compared with the no-chemotherapy group. Univariate (P = 0.383) and multivariate logistic analyses (P = 0.213) suggested that chemotherapy did not reduce the risk of distant metastasis. Furthermore, multivariate Cox regression analysis indicated that chemotherapy did not improve OS (P = 0.789) or PFS (P = 0.556). Conclusion: Platinum-based chemotherapy did not seem to provide a long-term survival advantage for patients with T4 SNACC and might be associated with worse outcomes after 5 years, although these findings need confirmation through prospective studies.

Source: Frontiers in Pharmacology

DOI: 10.3389/fphar.2025.1623242

Authors: Xinmao Song, Ji Sun, Gang Yang, Xiaoshen Wang, Li Wang

Institutions: Shanghai Medical College of Fudan University, Fudan University, Eye & ENT Hospital of Fudan University

Language: English

Topic: Head and Neck Surgical Oncology

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801